Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin.

Clinical case reports

Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES.
PMID: 28396749
Clin Case Rep. 2017 Feb 03;5(4):371-375. doi: 10.1002/ccr3.841. eCollection 2017 Apr.

This case suggests that initiation of HCV therapy immediately after liver transplantation with well-tolerated, all-oral regimens may achieve a virologic cure in HCV-positive recipients, thus preventing post-transplant HCV recurrence and associated disease progression. This strategy may broaden utilization of...

Cite
Poordad F, Lawitz E, Gutierrez JA, et al. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017;5(4):371-375doi: 10.1002/ccr3.841.
Poordad, F., Lawitz, E., Gutierrez, J. A., Guerrero, J., Speeg, K., & Swenson, E. S. (2017). An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clinical case reports, 5(4), 371-375. https://doi.org/10.1002/ccr3.841
Poordad, Fred, et al. "An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin." Clinical case reports vol. 5,4 (2017): 371-375. doi: https://doi.org/10.1002/ccr3.841
Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017 Feb 03;5(4):371-375. doi: 10.1002/ccr3.841. eCollection 2017 Apr. PMID: 28396749; PMCID: PMC5378822.
Copy Download .nbib Format: NLM
Expandable Polyaryl-Ether-Ether-Ketone Spacers for Interbody Distraction in the Lumbar Spine.

Global spine journal

Alimi M, Shin B, Macielak M, Hofstetter CP, Njoku I, Tsiouris AJ, Elowitz E, Härtl R.
PMID: 26131383
Global Spine J. 2015 Jun;5(3):169-78. doi: 10.1055/s-0035-1552988.

Study Design Retrospective case series. Objective StaXx XD (Spine Wave, Inc., Shelton, CT, United States) is an expandable polyaryl-ether-ether-ketone (PEEK) wafer implant utilized in the treatment of lumbar degenerative disease. PEEK implants have been successfully used as interbody devices....

Cite
Alimi M, Shin B, Macielak M, et al. Expandable Polyaryl-Ether-Ether-Ketone Spacers for Interbody Distraction in the Lumbar Spine. Global Spine J. 2015;5(3):169-78doi: 10.1055/s-0035-1552988.
Alimi, M., Shin, B., Macielak, M., Hofstetter, C. P., Njoku, I., Tsiouris, A. J., Elowitz, E., & Härtl, R. (2015). Expandable Polyaryl-Ether-Ether-Ketone Spacers for Interbody Distraction in the Lumbar Spine. Global spine journal, 5(3), 169-78. https://doi.org/10.1055/s-0035-1552988
Alimi, Marjan, et al. "Expandable Polyaryl-Ether-Ether-Ketone Spacers for Interbody Distraction in the Lumbar Spine." Global spine journal vol. 5,3 (2015): 169-78. doi: https://doi.org/10.1055/s-0035-1552988
Alimi M, Shin B, Macielak M, Hofstetter CP, Njoku I, Tsiouris AJ, Elowitz E, Härtl R. Expandable Polyaryl-Ether-Ether-Ketone Spacers for Interbody Distraction in the Lumbar Spine. Global Spine J. 2015 Jun;5(3):169-78. doi: 10.1055/s-0035-1552988. PMID: 26131383; PMCID: PMC4472284.
Copy Download .nbib Format: NLM
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.

Journal of hepatology

Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N.
PMID: 34740705
J Hepatol. 2021 Nov 02; doi: 10.1016/j.jhep.2021.10.018. Epub 2021 Nov 02.

BACKGROUND & AIMS: EDP-305 is an oral farnesoid X receptor (FXR) agonist under development for treating nonalcoholic steatohepatitis (NASH). The efficacy, safety, and tolerability of EDP-305 was evaluated in a Phase 2, randomized, double-blind, placebo-controlled study.METHODS: Non-cirrhotic patients with...

Cite
Ratziu V, Rinella ME, Neuschwander-Tetri BA, et al. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2021;doi: 10.1016/j.jhep.2021.10.018.
Ratziu, V., Rinella, M. E., Neuschwander-Tetri, B. A., Lawitz, E., Denham, D., Kayali, Z., Sheikh, A., Kowdley, K. V., Desta, T., Elkhashab, M., DeGrauw, J., Goodwin, B., Ahmad, A., & Adda, N. (2021). EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. Journal of hepatology, . https://doi.org/10.1016/j.jhep.2021.10.018
Ratziu, Vlad, et al. "EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study." Journal of hepatology vol. (2021). doi: https://doi.org/10.1016/j.jhep.2021.10.018
Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2021 Nov 02; doi: 10.1016/j.jhep.2021.10.018. Epub 2021 Nov 02. PMID: 34740705.
Copy Download .nbib Format: NLM
Chiral motion in colloidal electrophoresis.

Physical review. E

Braverman L, Mowitz A, Witten TA.
PMID: 32688502
Phys Rev E. 2020 Jun;101(6):062608. doi: 10.1103/PhysRevE.101.062608.

Asymmetrically charged, nonspherical colloidal particles in general perform complex rotations and oblique motions under an electric field. The interplay of electrostatic and hydrodynamic forces complicates the prediction of these motions. We demonstrate a method of calculating the body tensors...

Cite
Braverman L, Mowitz A, Witten TA. Chiral motion in colloidal electrophoresis. Phys Rev E. 2020;101(6):062608doi: 10.1103/PhysRevE.101.062608.
Braverman, L., Mowitz, A., & Witten, T. A. (2020). Chiral motion in colloidal electrophoresis. Physical review. E, 101(6), 062608. https://doi.org/10.1103/PhysRevE.101.062608
Braverman, Lara, et al. "Chiral motion in colloidal electrophoresis." Physical review. E vol. 101,6 (2020): 062608. doi: https://doi.org/10.1103/PhysRevE.101.062608
Braverman L, Mowitz A, Witten TA. Chiral motion in colloidal electrophoresis. Phys Rev E. 2020 Jun;101(6):062608. doi: 10.1103/PhysRevE.101.062608. PMID: 32688502.
Copy Download .nbib Format: NLM
Quality improvement and practice-based research in sleep medicine using structured clinical documentation in the electronic medical record.

Sleep science and practice

Maraganore DM, Freedom T, Simon KC, Lovitz LE, Musleh C, Munson R, Nasir N, Patel S, Paul J, Viola-Saltzman M, Meyers S, Chesis R, Hillman L, Tideman S, Pham A, Vazquez RM, Frigerio R.
PMID: 32395635
Sleep Sci Pract. 2020 Jan 02;4:1. doi: 10.1186/s41606-019-0038-2.

BACKGROUND: We developed and implemented a structured clinical documentation support (SCDS) toolkit within the electronic medical record, to optimize patient care, facilitate documentation, and capture data at office visits in a sleep medicine/neurology clinic for patient care and research...

Cite
Maraganore DM, Freedom T, Simon KC, et al. Quality improvement and practice-based research in sleep medicine using structured clinical documentation in the electronic medical record. Sleep Sci Pract. 2020;4:1doi: 10.1186/s41606-019-0038-2.
Maraganore, D. M., Freedom, T., Simon, K. C., Lovitz, L. E., Musleh, C., Munson, R., Nasir, N., Patel, S., Paul, J., Viola-Saltzman, M., Meyers, S., Chesis, R., Hillman, L., Tideman, S., Pham, A., Vazquez, R. M., & Frigerio, R. (2020). Quality improvement and practice-based research in sleep medicine using structured clinical documentation in the electronic medical record. Sleep science and practice, 41. https://doi.org/10.1186/s41606-019-0038-2
Maraganore, Demetrius M, et al. "Quality improvement and practice-based research in sleep medicine using structured clinical documentation in the electronic medical record." Sleep science and practice vol. 4 (2020): 1. doi: https://doi.org/10.1186/s41606-019-0038-2
Maraganore DM, Freedom T, Simon KC, Lovitz LE, Musleh C, Munson R, Nasir N, Patel S, Paul J, Viola-Saltzman M, Meyers S, Chesis R, Hillman L, Tideman S, Pham A, Vazquez RM, Frigerio R. Quality improvement and practice-based research in sleep medicine using structured clinical documentation in the electronic medical record. Sleep Sci Pract. 2020 Jan 02;4:1. doi: 10.1186/s41606-019-0038-2. PMID: 32395635; PMCID: PMC7213673.
Copy Download .nbib Format: NLM
Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.

PloS one

Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, Hatcho K, Lawitz E, Lopez R, Feldstein AE.
PMID: 30286196
PLoS One. 2018 Oct 04;13(10):e0205541. doi: 10.1371/journal.pone.0205541. eCollection 2018.

[This corrects the article DOI: 10.1371/journal.pone.0202226.].

Cite
Alkhouri N, Johnson C, Adams L, et al. Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. PLoS One. 2018;13(10):e0205541doi: 10.1371/journal.pone.0205541.
Alkhouri, N., Johnson, C., Adams, L., Kitajima, S., Tsuruno, C., Colpitts, T. L., Hatcho, K., Lawitz, E., Lopez, R., & Feldstein, A. E. (2018). Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. PloS one, 13(10), e0205541. https://doi.org/10.1371/journal.pone.0205541
Alkhouri, Naim, et al. "Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis." PloS one vol. 13,10 (2018): e0205541. doi: https://doi.org/10.1371/journal.pone.0205541
Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, Hatcho K, Lawitz E, Lopez R, Feldstein AE. Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. PLoS One. 2018 Oct 04;13(10):e0205541. doi: 10.1371/journal.pone.0205541. eCollection 2018. PMID: 30286196; PMCID: PMC6171937.
Copy Download .nbib Format: NLM
Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device.

Patient preference and adherence

Varunok P, Lawitz E, Beavers KL, Matusow G, Leong R, Lambert N, Bernaards C, Solsky J, Brennan BJ, Wat C, Bertasso A.
PMID: 22163158
Patient Prefer Adherence. 2011;5:587-99. doi: 10.2147/PPA.S26566. Epub 2011 Nov 24.

BACKGROUND: Peginterferon alfa-2a (40 kDa) is currently administered using a prefilled syringe. The peginterferon alfa-2a disposable autoinjector is a new safety-engineered device designed to facilitate injection and reduce the risk of needlestick injuries. The analysis of two open-label Phase...

Cite
Varunok P, Lawitz E, Beavers KL, et al. Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. Patient Prefer Adherence. 2011;5:587-99doi: 10.2147/PPA.S26566.
Varunok, P., Lawitz, E., Beavers, K. L., Matusow, G., Leong, R., Lambert, N., Bernaards, C., Solsky, J., Brennan, B. J., Wat, C., & Bertasso, A. (2011). Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. Patient preference and adherence, 5587-99. https://doi.org/10.2147/PPA.S26566
Varunok, Peter, et al. "Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device." Patient preference and adherence vol. 5 (2011): 587-99. doi: https://doi.org/10.2147/PPA.S26566
Varunok P, Lawitz E, Beavers KL, Matusow G, Leong R, Lambert N, Bernaards C, Solsky J, Brennan BJ, Wat C, Bertasso A. Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. Patient Prefer Adherence. 2011;5:587-99. doi: 10.2147/PPA.S26566. Epub 2011 Nov 24. PMID: 22163158; PMCID: PMC3234901.
Copy Download .nbib Format: NLM
XI. Uncomplicated Fractures of the Tarsal Scaphoid.

Annals of surgery

Horwitz AE.
PMID: 17863083
Ann Surg. 1913 Oct;58(4):526-32. doi: 10.1097/00000658-191310000-00011.

No abstract available.

Cite
Horwitz AE. XI. Uncomplicated Fractures of the Tarsal Scaphoid. Ann Surg. 1913;58(4):526-32doi: 10.1097/00000658-191310000-00011.
Horwitz, A. E. (1913). XI. Uncomplicated Fractures of the Tarsal Scaphoid. Annals of surgery, 58(4), 526-32. https://doi.org/10.1097/00000658-191310000-00011
Horwitz, A E. "XI. Uncomplicated Fractures of the Tarsal Scaphoid." Annals of surgery vol. 58,4 (1913): 526-32. doi: https://doi.org/10.1097/00000658-191310000-00011
Horwitz AE. XI. Uncomplicated Fractures of the Tarsal Scaphoid. Ann Surg. 1913 Oct;58(4):526-32. doi: 10.1097/00000658-191310000-00011. PMID: 17863083; PMCID: PMC1407580.
Copy Download .nbib Format: NLM
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study.

Health science reports

Lawitz E, Poordad F, Gutierrez JA, Beumont M, Beets G, Vandevoorde A, Remoortere PV, Luo D, Vijgen L, Eygen VV, Gamil M.
PMID: 32270053
Health Sci Rep. 2020 Feb 22;3(2):e145. doi: 10.1002/hsr2.145. eCollection 2020 Jun.

BACKGROUND AND AIMS: Direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult-to-cure/cirrhotic patients typically require a longer treatment duration...

Cite
Lawitz E, Poordad F, Gutierrez JA, et al. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health Sci Rep. 2020;3(2):e145doi: 10.1002/hsr2.145.
Lawitz, E., Poordad, F., Gutierrez, J. A., Beumont, M., Beets, G., Vandevoorde, A., Remoortere, P. V., Luo, D., Vijgen, L., Eygen, V. V., & Gamil, M. (2020). Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health science reports, 3(2), e145. https://doi.org/10.1002/hsr2.145
Lawitz, Eric, et al. "Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study." Health science reports vol. 3,2 (2020): e145. doi: https://doi.org/10.1002/hsr2.145
Lawitz E, Poordad F, Gutierrez JA, Beumont M, Beets G, Vandevoorde A, Remoortere PV, Luo D, Vijgen L, Eygen VV, Gamil M. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health Sci Rep. 2020 Feb 22;3(2):e145. doi: 10.1002/hsr2.145. eCollection 2020 Jun. PMID: 32270053; PMCID: PMC7136481.
Copy Download .nbib Format: NLM
Predicting tensorial electrophoretic effects in asymmetric colloids.

Physical review. E

Mowitz AJ, Witten TA.
PMID: 29347303
Phys Rev E. 2017 Dec;96(6):062613. doi: 10.1103/PhysRevE.96.062613. Epub 2017 Dec 20.

We formulate a numerical method for predicting the tensorial linear response of a rigid, asymmetrically charged body to an applied electric field. This prediction requires calculating the response of the fluid to the Stokes drag forces on the moving...

Cite
Mowitz AJ, Witten TA. Predicting tensorial electrophoretic effects in asymmetric colloids. Phys Rev E. 2017;96(6):062613doi: 10.1103/PhysRevE.96.062613.
Mowitz, A. J., & Witten, T. A. (2017). Predicting tensorial electrophoretic effects in asymmetric colloids. Physical review. E, 96(6), 062613. https://doi.org/10.1103/PhysRevE.96.062613
Mowitz, Aaron J, and Witten, T A. "Predicting tensorial electrophoretic effects in asymmetric colloids." Physical review. E vol. 96,6 (2017): 062613. doi: https://doi.org/10.1103/PhysRevE.96.062613
Mowitz AJ, Witten TA. Predicting tensorial electrophoretic effects in asymmetric colloids. Phys Rev E. 2017 Dec;96(6):062613. doi: 10.1103/PhysRevE.96.062613. Epub 2017 Dec 20. PMID: 29347303.
Copy Download .nbib Format: NLM
Performance of the GHS Mixtures Equation for Predicting Acute Oral Toxicity.

Regulatory toxicology and pharmacology : RTP

Hamm J, Allen D, Ceger P, Flint T, Lowit A, O'Dell L, Tao J, Kleinstreuer N.
PMID: 34298086
Regul Toxicol Pharmacol. 2021 Oct;125:105007. doi: 10.1016/j.yrtph.2021.105007. Epub 2021 Jul 20.

Acute oral toxicity classifications are based on the estimated chemical dose causing lethality in 50 % of laboratory animals tested (LD

Cite
Hamm J, Allen D, Ceger P, et al. Performance of the GHS Mixtures Equation for Predicting Acute Oral Toxicity. Regul Toxicol Pharmacol. 2021;125:105007doi: 10.1016/j.yrtph.2021.105007.
Hamm, J., Allen, D., Ceger, P., Flint, T., Lowit, A., O'Dell, L., Tao, J., & Kleinstreuer, N. (2021). Performance of the GHS Mixtures Equation for Predicting Acute Oral Toxicity. Regulatory toxicology and pharmacology : RTP, 125105007. https://doi.org/10.1016/j.yrtph.2021.105007
Hamm, Jon, et al. "Performance of the GHS Mixtures Equation for Predicting Acute Oral Toxicity." Regulatory toxicology and pharmacology : RTP vol. 125 (2021): 105007. doi: https://doi.org/10.1016/j.yrtph.2021.105007
Hamm J, Allen D, Ceger P, Flint T, Lowit A, O'Dell L, Tao J, Kleinstreuer N. Performance of the GHS Mixtures Equation for Predicting Acute Oral Toxicity. Regul Toxicol Pharmacol. 2021 Oct;125:105007. doi: 10.1016/j.yrtph.2021.105007. Epub 2021 Jul 20. PMID: 34298086.
Copy Download .nbib Format: NLM
Advertising's role in student nurse recruitment.

Hospitals

LOWITZ AC.
PMID: 14880150
Hospitals. 1951 Dec;25(12):44-6.

No abstract available.

Cite
LOWITZ AC. Advertising's role in student nurse recruitment. Hospitals. 1951;25(12):44-6
LOWITZ, A. C. (1951). Advertising's role in student nurse recruitment. Hospitals, 25(12), 44-6.
LOWITZ, A C. "Advertising's role in student nurse recruitment." Hospitals vol. 25,12 (1951): 44-6.
LOWITZ AC. Advertising's role in student nurse recruitment. Hospitals. 1951 Dec;25(12):44-6. PMID: 14880150.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries